NAFDAC Recalls Embacef 125 Suspension From Nationwide Market Following Complaint in Ekiti

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued an urgent recall of Embacef 125 Powder for Oral Suspension following confirmed reports of poor quality from a complaint lodged in Ekiti State.

The affected batch, PEDSE001, manufactured in February 2025 and expiring in January 2027, has been ordered off the market. Embassy Pharmaceutical and Chemicals Ltd, Lagos, the product’s registration holder, alongside its manufacturer, Laborate Pharmaceutical India, must withdraw the suspension due to safety concerns arising from the reconstituted medication caking within the first day of use.

Embacef 125 contains Cefuroxime Axetil, an antibiotic used to treat infections including bronchitis, gonorrhoea, Lyme disease, and various skin, ear, sinus, throat, tonsil, and urinary tract infections. NAFDAC warns that substandard antibiotics risk ineffective treatment and could encourage antibiotic resistance.

The agency urges all zonal directors and state coordinators to intensify efforts to remove the product and encourages healthcare professionals and consumers to purchase medicines only from authorised sources, checking product authenticity carefully.

Anyone suspecting substandard or counterfeit medicines is encouraged to report via NAFDAC’s toll-free line 0800-162-3322 or email sf.alert@nafdac.gov.ng.

This swift action highlights NAFDAC’s commitment to safeguarding public health across Nigeria by ensuring access to safe and effective medications.